GS or MS: Which IB Stock Should You Buy on Solid 2026 Prospects?

Goldman Sachs and Morgan Stanley both benefited from a 2025 rebound in M&A and capital markets activity: Goldman’s investment-banking revenues rose 19% y/y in the first nine months and it advised on over $1 trillion of announced M&A, while Morgan Stanley’s Asia revenues jumped 29.3% y/y to $7.27 billion and total client assets reached $8.9 trillion by September-end. Valuation and fundamentals diverge — GS trades at a 12‑month forward P/E of 16.34x (vs industry 15.09x) with a 1.78% dividend yield and 15.29% ROE, while MS trades at 17.29x with a 2.23% yield and 16.4% ROE — and analysts project 2025 revenue/earnings growth of +10.8%/+20.8% for GS versus +13.4%/+24.3% for MS. Both firms are accelerating asset & wealth management and private-markets initiatives (GS targets $300B private credit by 2029; MS continuing acquisitive expansion), leaving GS as the relatively cheaper value play and MS as the higher-growth, yield-supporting option for 2026 investors.

Analysis

Market structure: Top-tier IBs (GS, MS), global asset managers (TROW) and private-equity lenders are primary beneficiaries as M&A fees and capital markets issuance recover; Goldman’s reported >$1T of advised M&A and MS’s Japan tie (MUFG) mechanically steal fee share from mid-tier banks. Supply/demand: deal supply is elevated vs. muted 2022–24 levels, raising fee pricing power for elite banks but increasing execution competition for large syndicates; private credit supply will expand as GS targets $300bn by 2029, pressuring spreads in leveraged lending.

Risk assessment: Tail risks include abrupt policy/regulatory shifts (tariffs, clampdowns on buyouts), a rate-repricing that removes M&A financing glue, or a material liquidity event at a private-credit counterparty; expect market noise in days (earnings/Fed minutes), directional moves in 3–6 months (Fed cuts on/off), and strategic outcomes in 12–36 months (AWM scale, ROE convergence). Hidden dependencies: AWM growth relies on sustained retail/PE inflows and successful ETF/partnership rollouts; MS’s Japan strength is contingent on MUFG tranche renewals. Key catalysts: Fed easing cadence, large announced megadeals, and quarterly AUM/fee trends.

Trade implications: Favor relative-value and yield-capture vs. pure directional exposure—volatility likely around earnings and Fed windows. Cross-assets: dovish Fed + improved risk appetite → lower Treasury yields (support for duration) and weaker USD; commodity sensitivity limited but risk-on could lift industrial metals and oil on deal-driven capex.

Contrarian angles: Consensus underestimates execution/credit risk of rapidly scaling private-credit arms (liquidity & mark-to-market shocks). MS’s higher P/E and ROE imply expectations priced for near-term outperformance — a shortable vulnerability if AUM flows disappoint; GS’s cheaper multiple (16.3x vs 17.3x forward P/E) could re-rate higher with two positive M&A quarters, making it a value asymmetric bet.

Key Decisions for Investors

• Initiate a dollar-neutral pair trade: long GS (2.0% portfolio) and short MS (2.0% portfolio) to capture valuation gap; target GS outperformance of 8% within 6–12 months. Use a stop-loss if GS underperforms MS by >12% over any 90-day rolling window or unwind if MS reports AUM growth >+5% QoQ.
• Tactically overweight MS (2.5% portfolio) via covered-call income: buy shares and sell 3-month calls 8–12% OTM, roll quarterly. Exit or reduce if quarterly AUM/net inflows fall below +2% QoQ or dividend guidance is cut.
• Add asymmetric long exposure to GS via a 12-month call spread sized 1.5% portfolio if forward P/E ≤16.5 or if GS IB revenues accelerate >+12% YoY across two consecutive quarters; cap downside by selling 25% OTM call leg.
• Buy macro insurance: allocate 2.0% to long-duration Treasuries (TLT or 10y futures) as hedge against Fed-policy shocks or risk-off (target 3–9 month duration). Trim if 10-year yield rises above 4.5% or if Fed guidance confirms three+ cuts priced by mid-2026.